Sarcomatoid differentiation in renal cell carcinoma (sRCC) is a rare but aggressive histological feature associated with rapid progression, poor response to targeted therapy, and significantly worse survival.
Current diagnosis of sRCC requires tissue biopsy and histopathological analysis, which may miss focal sarcomatoid regions due to sampling error and cannot be performed preoperatively in all patients.
Non-invasive imaging tools that can reliably detect sarcomatoid differentiation would dramatically change surgical planning, systemic therapy selection, and prognostic counseling.
This study explores whether multiparametric MRI (mpMRI) combined with machine learning can identify sRCC non-invasively, comparing sarcomatoid and non-sarcomatoid tumors on four MRI sequences.
The study enrolled 32 subjects matched 1:1 -- 16 with confirmed sarcomatoid RCC and 16 with non-sarcomatoid RCC -- with all patients undergoing preoperative mpMRI.
Four MRI sequences were used: T2-weighted (T2W), T1-weighted (T1W), arterial-phase contrast-enhanced T1W (T1W-CEart), and venous-phase contrast-enhanced T1W (T1W-CEven).
A Self-Organizing Map (SOM) with a 9x9 Kohonen architecture was trained on the four-channel MRI input, projecting high-dimensional imaging data into a 2D Activation Map that captures learned spatial patterns.
These 2D Activation Maps were then used as input to a Learning Vector Quantizer (LVQ), a supervised classifier trained to distinguish sRCC from nsRCC based on the SOM-derived representations.
Self-Organizing Maps are unsupervised neural networks that learn a topologically ordered representation of input data, preserving the neighborhood structure of the feature space in a lower-dimensional output grid.
Training the SOM on four concurrent MRI channels allows it to discover patterns of co-variation across imaging sequences that are not visible in any single channel alone.
The resulting 2D Activation Map encodes which SOM nodes were most strongly activated by each patient's tumor region, creating a compact but information-rich representation of multi-channel MRI data.
This dimensionality reduction enables the LVQ to classify tumors based on learned mpMRI patterns without requiring manual feature engineering or radiologist input.
The SOM-LVQ pipeline achieved 93.75% accuracy on the training set, demonstrating that the model learned meaningful discriminative patterns from the mpMRI Activation Maps.
On the validation set, accuracy was 83.33%, and on the independent test set it was 70%, reflecting expected performance degradation on unseen data given the small overall sample size.
Qualitative analysis showed that sRCC tumors were characteristically hypointense on T1W, T1W-art, and T1W-ven sequences, suggesting reduced vascularity and altered tissue composition compared to nsRCC.
These imaging signatures are consistent with the known biology of sRCC, which often features extensive necrosis and fibrosis that alter contrast enhancement patterns.
The most significant limitation of this study is its small sample size of 32 patients, which limits statistical power and the reliability of performance estimates.
The test set accuracy of 70% may reflect overfitting to the training cohort or the inherent difficulty of the classification task, and cannot be considered definitive without larger validation.
sRCC itself is biologically heterogeneous, encompassing multiple histological subtypes and degrees of sarcomatoid transformation, which may introduce variability that a small dataset cannot fully characterize.
Future work with larger, multi-institutional cohorts is needed to confirm whether mpMRI-based SOM-LVQ classification can achieve clinically acceptable performance for preoperative sRCC detection.
This proof-of-concept study demonstrates that machine learning on multiparametric MRI can capture imaging signatures that differentiate sarcomatoid from non-sarcomatoid renal tumors.
If validated in larger cohorts, this approach could provide preoperative sRCC identification that currently requires biopsy, enabling earlier initiation of appropriate systemic therapy.
The SOM-LVQ framework is generalizable and could be applied to other histological classification challenges in renal and urological oncology beyond sRCC detection.
Combining mpMRI-based classification with emerging immunotherapy biomarkers could eventually create a comprehensive non-invasive decision support system for aggressive RCC subtypes.